#2 - Regeneron Pharmaceuticals (NASDAQ:REGN)
With a forward P/E ratio of over 30x, Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) presents concerns about valuation that may weigh more heavily on investors’ minds than its beta of just 0.12. However, it’s worth noting that Regeneron is the largest holding in The iShares Biotechnology ETF (NASDAQ: IBB).
That's not without reason. Regeneron has two blockbuster drugs that contribute to the bottom line. First is Dupixent which it shares the rights to with Sanofi (NASDAQ: SNY). Dupixent generated $11.6 billion in sales in 2023, and Regeneron just reported positive results in two Phase 3 trials that will allow the drug to be used for chronic obstructive pulmonary disease (COPD). Analysts believe that could contribute $3.5 billion to revenue on the low end.
The company also has Eylea, a treatment for wet age-related macular degeneration, which it shares the rights to with Bayer. The significance to investors is that the company is approved for a high-dose formulation that has allowed it to offset competition with biosimilar offerings.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Read More - Current Price
- $750.74
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 18 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $1,099.55 (46.5% Upside)
